Point-of-Care Diagnostics Market Size, Share, Growth, and Forecast 2032 : BAMG Consulting

Point-of-Care Diagnostics Market Worth $74.9 Billion By 2032, Driven by Rising Demand for Rapid Testing, Decentralized Healthcare and AI-Enabled Diagnostic Solutions – New Report by BMAG Consulting

New Delhi, India – September 13, 2026: BMAG Consulting, a global market research and strategic advisory firm, has published its latest report titled “Point-of-Care Diagnostics Market. The report provides a comprehensive analysis of the global point-of-care diagnostics market, covering market dynamics, rapid-testing technologies, decentralized healthcare trends, product and platform segmentation, end-user adoption, regional opportunities, competitive landscape, technological developments, and strategic growth prospects.

According to BMAG Consulting, the global Point-of-Care Diagnostics Market was valued at USD 34.6 billion in 2024 and is projected to reach USD 74.9 billion by 2032, registering a CAGR of 9.1% during 2025–2032. North America holds the dominant position, supported by advanced healthcare infrastructure, widespread adoption of decentralized testing, and the presence of leading diagnostic manufacturers. Asia-Pacific is expected to register the fastest growth during the forecast period.

Download Free Sample

Access an executive summary, market insights, segmentation analysis, regional outlook, competitive intelligence, and strategic opportunities from the Point-of-Care Diagnostics Market Report.

https://bmagconsulting.com/sample/point-of-care-diagnostics-market

MARKET: KEY INSIGHTS

Market Overview

Point-of-care diagnostics are transforming healthcare delivery by enabling diagnostic testing at or near the location of patient care, reducing dependence on centralized laboratories and allowing healthcare professionals to make faster clinical decisions.

Healthcare systems worldwide are increasingly shifting toward decentralized and near-patient testing models because of the need for faster turnaround times, lower healthcare costs, improved patient outcomes, and more accessible diagnostic services.

The growing burden of chronic diseases such as diabetes and cardiovascular disorders, combined with an ageing global population, is strengthening demand for easy-to-use diagnostic devices that can operate outside traditional laboratory environments.

Technological advances in microfluidics, biosensors, molecular diagnostics, artificial intelligence, connectivity, and portable testing platforms are improving the accuracy, reliability, and functionality of point-of-care devices. The expansion of home healthcare and remote patient monitoring is further broadening the addressable market.

View full report

https://bmagconsulting.com/report/point-of-care-diagnostics-market

Key Market Drivers & Trends

Growing Demand for Rapid and Decentralized Testing:
Healthcare providers are increasingly adopting point-of-care testing to obtain diagnostic results rapidly in emergency departments, clinics, ambulatory settings, remote locations, and home-care environments.

Rising Prevalence of Chronic Diseases:
The growing global burden of diabetes, cardiovascular disease, cancer, and other chronic conditions is creating sustained demand for frequent monitoring and rapid diagnostic testing.

Persistent Infectious Disease Burden:
HIV, hepatitis, tuberculosis, malaria, influenza, COVID-19, and other infectious diseases continue to support demand for rapid diagnostic solutions, particularly in regions with limited centralized laboratory infrastructure.

Integration of Artificial Intelligence:
AI and machine learning are increasingly being incorporated into point-of-care diagnostic systems to improve test interpretation, recognize patterns, reduce human error, and support faster clinical decision-making.

Connected Diagnostic Devices:
Wireless connectivity is enabling point-of-care systems to transmit test results directly to electronic health records and cloud-based platforms, supporting remote monitoring and integrated digital-health workflows.

Expansion of Multiplex and Syndromic Testing:
Multiplex platforms capable of detecting multiple pathogens or biomarkers from a single sample are gaining importance because they can accelerate diagnosis and help clinicians make more informed treatment decisions.

Growth of Home-Based Testing:
Consumer demand for convenient healthcare is accelerating the adoption of self-testing and home-based diagnostic technologies, particularly for chronic disease monitoring, infectious disease screening, pregnancy testing, and other routine applications.

Advances in Molecular Diagnostics and Microfluidics:
Miniaturized molecular diagnostic platforms and microfluidic technologies are improving sensitivity, portability, speed, and laboratory-comparable performance in decentralized environments.

Increasing Healthcare Access in Emerging Markets:
Governments and healthcare organizations are investing in decentralized testing infrastructure across emerging economies to improve disease surveillance, screening, and access to essential diagnostics.

Regulatory and Reimbursement Challenges:
Stringent regulatory requirements, clinical-validation demands, inconsistent reimbursement policies, and concerns regarding standardization and operator variability remain important barriers to broader adoption.

Segmentation Insights

The Point-of-Care Diagnostics Market is segmented based on:

By Product

• Glucose Monitoring Kits

• Infectious Disease Testing Kits

• Cardiac Markers

• Coagulation Monitoring Kits

• Pregnancy & Fertility Testing Kits

• Cholesterol Test Kits

• Cancer Markers

• Hematology Testing

• Others

By Platform

• Lateral Flow Assays

• Immunoassay-Based

• Molecular Diagnostics

• Microfluidics

• Dipsticks & Test Strips

By End User

• Hospitals & Clinics

• Diagnostic Laboratories

• Home Care Settings

• Ambulatory Care Centers

• Academic & Research Institutes

By Distribution Channel

• Over-The-Counter

• Prescription-Based

By Region

• North America

• Europe

• Asia-Pacific

• Latin America

• Middle East & Africa

Regional Insights

North America dominates the global point-of-care diagnostics market. The region benefits from advanced healthcare infrastructure, high healthcare expenditure, strong adoption of decentralized testing, and the presence of major diagnostic companies including Abbott Laboratories and Danaher Corporation.

The United States represents a particularly important market because of the widespread adoption of point-of-care testing in hospitals, clinics, emergency settings, and home care. The region's ageing population and increasing prevalence of chronic diseases are expected to sustain demand for glucose monitoring, cardiac testing, infectious disease diagnostics, and other rapid-testing solutions.

Asia-Pacific is expected to experience the fastest growth during the forecast period. Expanding healthcare access, rising disease burden, growing healthcare investment, and the need for decentralized diagnostic infrastructure are creating significant opportunities across China, India, Japan, Australia, South Korea, and other regional markets.

Emerging economies are increasingly investing in rapid infectious-disease testing and decentralized healthcare systems to improve disease surveillance and reach underserved populations.

Europe remains an important market, supported by established healthcare systems, diagnostic infrastructure, technological innovation, and growing demand for rapid and home-based testing solutions.

Competitive Landscape

The global point-of-care diagnostics market is characterized by intense competition between established multinational diagnostic companies and innovative technology-focused companies.

Key companies profiled by BMAG Consulting include:

• Abbott Laboratories

• Roche Diagnostics

• Danaher Corporation

• Cepheid

• Radiometer

• Siemens Healthineers

• Becton, Dickinson and Company (BD)

• Quidel Corporation (QuidelOrtho)

• Bio-Rad Laboratories

• Trinity Biotech

• Nova Biomedical

• PTS Diagnostics

• Chembio Diagnostics

• OraSure Technologies

Companies are competing on diagnostic accuracy, testing speed, portability, connectivity, regulatory approvals, test-menu breadth, multiplexing capabilities, and cost efficiency.

Leading manufacturers are increasingly investing in miniaturized platforms, molecular diagnostics, biosensors, connected devices, AI-powered interpretation, and expanded infectious-disease test menus. Strategic partnerships, acquisitions, manufacturing expansion, and distribution agreements are also being used to strengthen geographic reach and technology portfolios.

Recent Industry Developments

• In 2023, Abbott received expanded regulatory clearance for its point-of-care testing platform, broadening its infectious-disease test menu to support additional respiratory pathogen detection.

• In 2023, Roche Diagnostics announced the launch of an enhanced connected point-of-care testing system designed to integrate directly with hospital electronic health-record systems, supporting improved data interoperability for healthcare professionals.

These developments highlight the industry's movement toward connected diagnostics, broader infectious-disease testing, digital-health integration, and decentralized clinical decision-making.

About BMAG Consulting

BMAG Consulting is a global market research and strategic advisory firm providing actionable market intelligence across healthcare, life sciences, technology, chemicals, energy, food & beverage, automotive, aerospace & defense, and other high-growth industries.

BMAG Consulting delivers market sizing, competitive intelligence, strategic consulting, opportunity assessment, industry forecasting, and customized research solutions to help organizations identify emerging opportunities and make informed business decisions.

Media Contact

BMAG Consulting
Email: sales@bmagconsulting.com
Website: https://bmagconsulting.com